A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

ConclusionNeratinib and trametinib combination was toxic and had limited clinical efficacy. This may be due to suboptimal drug dosing given drug –drug interactions.Trial registration ID: NCT03065387.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research